Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2022

Aug 22, 2022

SELL
$1.22 - $1.73 $2,967 - $4,207
-2,432 Closed
0 $0
Q3 2021

Nov 15, 2021

BUY
$3.3 - $6.32 $2,247 - $4,303
681 Added 38.89%
2,432 $10,000
Q2 2021

Aug 12, 2021

BUY
$6.32 - $14.02 $11,066 - $24,549
1,751 New
1,751 $11,000

Others Institutions Holding GMTX

About Gemini Therapeutics, Inc.


  • Ticker GMTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 43,244,500
  • Market Cap $1.05B
  • Description
  • Gemini Therapeutics, Inc., a clinical stage precision medicine company, engages in developing various therapeutic compounds for treating genetically defined age-related macular degeneration (AMD). Its lead candidate is GEM103, a recombinant form of the human complement factor H protein to treat dry AMD patients. The company also develops GEM307 ...
More about GMTX
Track This Portfolio

Track Legal & General Group PLC Portfolio

Follow Legal & General Group PLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Legal & General Group PLC, based on Form 13F filings with the SEC.

News

Stay updated on Legal & General Group PLC with notifications on news.